<DOC>
	<DOCNO>NCT00725231</DOCNO>
	<brief_summary>Peripheral T cell lymphomas comprise 10-15 % malignant lymphoma . The prognosis significantly worse aggressive B cell lymphoma . The prospect elderly patient especially poor , estimated disease free survival 25 % three year . Previous phase II trial demonstrate significant activity monoclonal anti CD52 antibody alemtuzumab primary relapse T cell lymphoma . The investigator thus propose investigate value adjuvant alemtuzumab combination dose dense CHOP-14 patient previously untreated peripheral T cell lymphoma .</brief_summary>
	<brief_title>Immunotherapy Peripheral T Cell Lymphoma - Role Alemtuzumab Addition Dose Dense CHOP</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>risk group peripheral T cell lymphoma performance status ECOG 02 write consent measurable disease stage I N without bulky disease already initiate treatment serious accompany disorder impair organ function bone marrow involvement &gt; 25 % HIV positivity leukemic manifestation lymphoma simultaneous participation another trial platelet &lt; 100 000/ mm , leukocytes &lt; 2500 /mm</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>T cell lymphoma</keyword>
</DOC>